Seattle Genetics seeds a new immuno-oncology collaboration with the protein explorers at Pieris
The Seattle-based biotech is seeding a joint discovery effort that matches its successful work on antibody drug conjugates with Pieris’s Anticalin platform, getting the work started with a $30 million payment.
Should it all work out according to plan — always a long shot in biotech — Pieris can earn up to $1.2 billion in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.